Latest & greatest articles for calcium

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on calcium or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on calcium and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for calcium

301. Calcium for prevention of osteoporotic fractures in postmenopausal women

Calcium for prevention of osteoporotic fractures in postmenopausal women Calcium for prevention of osteoporotic fractures in postmenopausal women Calcium for prevention of osteoporotic fractures in postmenopausal women Cumming R G, Nevitt M C Authors' objectives To assess the effectiveness of calcium supplements and/or dietary calcium for the prevention of osteoporotic fractures in postmenopausal women. Searching The authors searched MEDLINE (1966 to March 1997) using the textwords 'fracture (...) ' and 'calcium'. All publications known to the authors and the reference lists of identified articles were also reviewed for additional relevant studies. Study selection Study designs of evaluations included in the review Randomised trials (RCTs) of calcium supplements; nonrandomised trials of calcium supplements; observational epidemiologic studies (cohort studies and case-control studies) of calcium supplements; and observational epidemiological studies (cohort studies and case- control studies) of dietary

DARE.1997

302. First- and second-year effects in trials of calcium supplementation on the loss of bone density in postmenopausal women

First- and second-year effects in trials of calcium supplementation on the loss of bone density in postmenopausal women First- and second-year effects in trials of calcium supplementation on the loss of bone density in postmenopausal women First- and second-year effects in trials of calcium supplementation on the loss of bone density in postmenopausal women Mackerras D, Lumley T Authors' objectives To determine if the effect of calcium on the loss of bone or bone density differs in the first (...) and second years after randomisation to calcium or control therapy. Searching MEDLINE was searched from 1990 to July 1996 for trials reported in the English language. The searches were conducted using the MeSH terms 'osteoporosis', 'hip fracture' or 'bone density', each combined with the following: 'calcium', 'calcium carbonate', 'calcium phosphate', 'calcium, dietary', 'diet', 'dairy products [administration & dosage]' or 'dairy products [therapeutic use]'. Studies were also identified from

DARE.1997

303. Effect of calcium antagonists on plasma norepinephrine levels, heart rate, and blood pressure

Effect of calcium antagonists on plasma norepinephrine levels, heart rate, and blood pressure Effect of calcium antagonists on plasma norepinephrine levels, heart rate, and blood pressure Effect of calcium antagonists on plasma norepinephrine levels, heart rate, and blood pressure Grossman E, Messerli F H Authors' objectives To evaluate the effects of calcium antagonists on sympathetic activity in hypertensive patients. Searching MEDLINE was searched for trials published in the English language (...) between 1975 and May 1996, using the terms 'calcium channel blockers' or 'calcium antagonists', 'sympathetic nervous system', and 'catecholamines'. Study selection Study designs of evaluations included in the review Clinical studies (no further details were provided) were included. Studies that did not include pre- and post-treatment blood-pressure and NE levels were excluded. Specific interventions included in the review Calcium antagonists including the following: phenyl alkylamines, e.g. verapamil

DARE.1997

304. Economic evaluation of the use of nadroparin calcium in the prophylaxis of deep vein thrombosis and pulmonary embolism in surgical patients in Italy

Economic evaluation of the use of nadroparin calcium in the prophylaxis of deep vein thrombosis and pulmonary embolism in surgical patients in Italy Economic evaluation of the use of nadroparin calcium in the prophylaxis of deep vein thrombosis and pulmonary embolism in surgical patients in Italy Economic evaluation of the use of nadroparin calcium in the prophylaxis of deep vein thrombosis and pulmonary embolism in surgical patients in Italy Lloyd A, Aitken J A, Hoffmeyer U K, Kelso E J (...) , Wakerly E C, Barber N D Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of nadroparin calcium (a low-molecular weight heparin (LMWH)) in the prophylaxis of deep vein thrombosis (DVT) and pulmonary embolism (PE). Type

NHS Economic Evaluation Database.1997

305. Short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in patients with primary hyperparathyroidism.

Short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in patients with primary hyperparathyroidism. 9366582 1997 11 20 1997 11 20 2016 11 24 0028-4793 337 21 1997 Nov 20 The New England journal of medicine N. Engl. J. Med. Short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in patients with primary hyperparathyroidism. 1506-10 Surgery is the usual therapy for patients with primary hyperparathyroidism. We investigated the ability (...) of a calcimimetic drug that inhibits parathyroid hormone secretion in vitro to decrease serum parathyroid hormone and calcium concentrations in patients with this disorder. We performed a randomized, placebo-controlled study of single oral doses of 4 to 160 mg of the calcium-receptor agonist drug R-568 in 20 postmenopausal women with mild primary hyperparathyroidism. At base line, the mean (+/-SE) serum calcium concentration was 10.7+/-0.2 mg per deciliter (2.67+/-0.05 mmol per liter). Serum parathyroid hormone

NEJM1997

306. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older.

Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. 9278463 1997 09 04 1997 09 04 2013 11 21 0028-4793 337 10 1997 Sep 04 The New England journal of medicine N. Engl. J. Med. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. 670-6 Inadequate dietary intake of calcium and vitamin D may contribute to the high prevalence of osteoporosis among older persons. We studied the effects (...) of three years of dietary supplementation with calcium and vitamin D on bone mineral density, biochemical measures of bone metabolism, and the incidence of nonvertebral fractures in 176 men and 213 women 65 years of age or older who were living at home. They received either 500 mg of calcium plus 700 IU of vitamin D3 (cholecalciferol) per day or placebo. Bone mineral density was measured by dual-energy x-ray absorptiometry, blood and urine were analyzed every six months, and cases of nonvertebral

NEJM1997

307. Trial of calcium to prevent preeclampsia.

Trial of calcium to prevent preeclampsia. 9211675 1997 07 15 1997 07 15 2013 11 21 0028-4793 337 2 1997 Jul 10 The New England journal of medicine N. Engl. J. Med. Trial of calcium to prevent preeclampsia. 69-76 Previous trials have suggested that calcium supplementation during pregnancy may reduce the risk of preeclampsia. However, differences in study design and a low dietary calcium intake in the populations studied limit acceptance of the data. We randomly assigned 4589 healthy nulliparous (...) women who were 13 to 21 weeks pregnant to receive daily treatment with either 2 g of elemental calcium or placebo for the remainder of their pregnancies. Surveillance for preeclampsia was conducted by personnel unaware of treatment-group assignments, using standardized measurements of blood pressure and urinary protein excretion at uniformly scheduled prenatal visits, protocols for monitoring these measurements during the hospitalization for delivery, and reviews of medical records of unscheduled

NEJM1997

308. Long-term effect of calcium supplementation during pregnancy on the blood pressure of offspring: follow up of a randomised controlled trial.

Long-term effect of calcium supplementation during pregnancy on the blood pressure of offspring: follow up of a randomised controlled trial. 9274547 1997 09 15 1997 09 15 2008 11 20 0959-8138 315 7103 1997 Aug 02 BMJ (Clinical research ed.) BMJ Long-term effect of calcium supplementation during pregnancy on the blood pressure of offspring: follow up of a randomised controlled trial. 281-5 To explore the long-term effect of calcium supplementation during pregnancy on the offspring's blood (...) pressure during childhood. Follow up of a population enrolled in a double blind, randomised, placebo controlled trial. Perinatal research unit, World Health Organisation's collaborative research centre. 591 children at a mean age of 7 years whose mothers were randomly assigned during pregnancy to receive 2 g/day of elemental calcium (n = 298) or placebo (n = 293). Mean blood pressure and rate of high blood pressure of children. Overall, systolic blood pressure was lower in the calcium group (mean difference

BMJ1997 Full Text: Link to full Text with Trip Pro

309. The effect of calcium supplementation on bone density during lactation and after weaning.

The effect of calcium supplementation on bone density during lactation and after weaning. 9262495 1997 08 21 1997 08 21 2013 11 21 0028-4793 337 8 1997 Aug 21 The New England journal of medicine N. Engl. J. Med. The effect of calcium supplementation on bone density during lactation and after weaning. 523-8 Women may lose bone during lactation because of calcium lost in breast milk. We studied whether calcium supplementation prevents bone loss during lactation or augments bone gain after weaning (...) . We conducted two randomized, placebo-controlled trials of calcium supplementation (1 g per day) in postpartum women. In one trial (the study of lactation), 97 lactating and 99 nonlactating women were enrolled a mean (+/-SD) of 16+/-2 days post partum. In the second trial (the study of weaning), 95 lactating women who weaned their infants in the 2 months after enrollment and 92 nonlactating women were enrolled 5.6+/-0.8 months post partum. The bone density of the total body, lumbar spine

NEJM1997

310. Safety of the calcium antagonist lacidipine evaluated from a phase III-IV trial database

Safety of the calcium antagonist lacidipine evaluated from a phase III-IV trial database Safety of the calcium antagonist lacidipine evaluated from a phase III-IV trial database Safety of the calcium antagonist lacidipine evaluated from a phase III-IV trial database Lindholm L H, Tcherdakoff P, Zanchetti A Authors' objectives To evaluate the safety of the calcium antagonist lacidipine in patients with hypertension. Searching The authors used the datafile held by the manufacturers of lacidipine (...) to identify trials completed before January 1, 1995. Study selection Study designs of evaluations included in the review Phase III-IV clinical trials. The data were equivalent to that from cohort studies. Specific interventions included in the review Calcium antagonists (lacidipine and unspecified others), diuretics, beta-blockers, angiotensin-converting enzyme inhibitors and placebo. Participants included in the review Patients with hypertension were included. Outcomes assessed in the review The outcomes

DARE.1996

311. Dietary calcium and blood pressure: a meta-analysis of randomized clinical trials

Dietary calcium and blood pressure: a meta-analysis of randomized clinical trials Dietary calcium and blood pressure: a meta-analysis of randomized clinical trials Dietary calcium and blood pressure: a meta-analysis of randomized clinical trials Allender P S, Cutler J A, Follmann D, Cappuccio F P, Pryer J, Elliott P Authors' objectives To assess the effect of dietary calcium supplementation on blood-pressure. Searching MEDLINE was searched from January 1982 to December 1993. Additional material (...) was obtained by handsearching major journals, reviewing abstracts from scientific meetings, and examining previous review articles. No restriction on publication language was stated. Study selection Study designs of evaluations included in the review Randomised clinical trials (RCTs) were included. Trials were excluded from the pooling if the calcium supplementation was part of a multifactorial trial. Specific interventions included in the review Calcium supplements (calcium carbonate, gluconate, yeast

DARE.1996

312. Effect of calcium supplementation on pregnancy-induced hypertension and preeclampsia: a meta-analysis of randomized controlled trials

Effect of calcium supplementation on pregnancy-induced hypertension and preeclampsia: a meta-analysis of randomized controlled trials Effect of calcium supplementation on pregnancy-induced hypertension and preeclampsia: a meta-analysis of randomized controlled trials Effect of calcium supplementation on pregnancy-induced hypertension and preeclampsia: a meta-analysis of randomized controlled trials Bucher H C, Guyatt G H, Cook R J, Hatala R, Cook D J, Lang J D, Hunt D L Authors' objectives (...) To review the effect of calcium supplementation during pregnancy on blood-pressure, pre-eclampsia and adverse outcomes of pregnancy. Searching MEDLINE and EMBASE were searched from 1966 to 1994 using the Cochrane Collaboration strategy and the keywords 'calcium' and 'hypertension' or 'blood pressure'. Citation searches of frequently identified articles were performed on SciSearch. Authors of eligible trials were contacted to ensure accuracy, completeness of data, and to identify unpublished trials

DARE.1996

313. Effects of dietary calcium supplementation on blood pressure: a meta-analysis of randomized controlled trials

Effects of dietary calcium supplementation on blood pressure: a meta-analysis of randomized controlled trials Effects of dietary calcium supplementation on blood pressure: a meta-analysis of randomized controlled trials Effects of dietary calcium supplementation on blood pressure: a meta-analysis of randomized controlled trials Bucher H, Cook R J, Guyatt G H, Lang J D, Cook D J, Hatala R, Hunt D L Authors' objectives To assess the impact of calcium supplementation on systolic and diastolic (...) blood-pressure in nonpregnant normotensive and hypertensive individuals. Searching MEDLINE and EMBASE were searched from 1966 to May 1994 using the Cochrane Collaboration strategy and the keywords 'calcium', 'hypertension' or 'blood pressure'. Reference lists of primary and review articles were examined, and authors were contacted for any additional studies. Study selection Study designs of evaluations included in the review Randomised controlled trials (RCTs) where the follow-up was for at least 2

DARE.1996

314. Calcium does not protect against colorectal neoplasia

Calcium does not protect against colorectal neoplasia Calcium does not protect against colorectal neoplasia Calcium does not protect against colorectal neoplasia Bergsma-Kadijk J A, van't Veer P, Kampman E, Burema J Authors' objectives To assess whether calcium decreases the risk of colorectal neoplasia by binding bowel-irritating compounds and diminishing mucosal proliferation. Searching MEDLINE was searched from January 1980 to September 1994 with the following keywords: 'site' ('colon (...) ', 'rectum', 'colorectal'), 'endpoint' ('cancer', 'carcinoma', 'tumour', 'polyps', 'hyperproliferation') and 'calcium' ('calcium diet', 'dietary', 'dairy'). Current Contents for 1994 (July to September) and the reference lists of retrieved papers were also examined. Study selection Study designs of evaluations included in the review Cohort and case-control studies were included. Specific interventions included in the review Calcium intake. Participants included in the review Men and women were included

DARE.1996

315. Clinical and economic effects of mupirocin calcium on preventing Staphylococcus aureus infection in hemodialysis patients: a decision analysis

Clinical and economic effects of mupirocin calcium on preventing Staphylococcus aureus infection in hemodialysis patients: a decision analysis Clinical and economic effects of mupirocin calcium on preventing Staphylococcus aureus infection in hemodialysis patients: a decision analysis Clinical and economic effects of mupirocin calcium on preventing Staphylococcus aureus infection in hemodialysis patients: a decision analysis Bloom B S, Fendrick A M, Chernew M E, Patel P Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The effect of mupirocin calcium on the prevention of Staphylococcus aureus (S aureus) infection in hemodialysis patients. Type of intervention Primary prevention and treatment. Economic study type Cost

NHS Economic Evaluation Database.1996

316. Synthetic human parathyroid hormone 1-34 vs calcitriol and calcium in the treatment of hypoparathyroidism.

Synthetic human parathyroid hormone 1-34 vs calcitriol and calcium in the treatment of hypoparathyroidism. 8773636 1996 09 26 1996 09 26 2016 10 17 0098-7484 276 8 1996 Aug 28 JAMA JAMA Synthetic human parathyroid hormone 1-34 vs calcitriol and calcium in the treatment of hypoparathyroidism. 631-6 To test the hypothesis that treatment with human parathyroid hormone 1-34 (PTH 1-34) can maintain normal serum calcium without hypercalciuria in patients with hypoparathyroidism. Randomized crossover (...) daily with supplemental calcium carbonate. Serum and urine calcium and phosphorus levels. Once-daily treatment with PTH 1-34 maintained serum calcium in the normal range with decreased urine calcium excretion (P<.05 at 2 weeks and P<.Ol at 10 weeks) compared with calcitriol treatment. Biochemical markers of bone turnover increased significantly (P<.Ol at 10 weeks) during PTH 1-34 treatment. Treatment of hypoparathyroidism with PTH 1-34 reduces urine calcium excretion compared with treatment

JAMA1996

317. Comparison of the effects of over-the-counter famotidine and calcium carbonate antacid on postprandial gastric acid. A randomized controlled trial.

Comparison of the effects of over-the-counter famotidine and calcium carbonate antacid on postprandial gastric acid. A randomized controlled trial. 8618369 1996 06 07 1996 06 07 2016 10 17 0098-7484 275 18 1996 May 08 JAMA JAMA Comparison of the effects of over-the-counter famotidine and calcium carbonate antacid on postprandial gastric acid. A randomized controlled trial. 1428-31 To compare an over-the-counter histamine2-receptor antagonist with an antacid as gastric acid reducers. Randomized (...) , double-blind, placebo-controlled crossover trial. Gastric secretory research laboratory in a Veterans Affairs medical center. Eighteen healthy volunteers (10 men and 8 women) aged 25 to 62 years with normal gastric acid secretion rates. The subjects received the histamine2-receptor antagonist famotidine (Pepcid AC, 10 mg), calcium carbonate antacid tablets (Tums, 1000 mg), or placebo medications 1 hour after a test meal. Two identical meals were taken 2.5 and 6.0 hours after the medication was given

JAMA1996

318. A meta-analysis of the effect of calcium intake on bone mass in young and middle aged females and males

A meta-analysis of the effect of calcium intake on bone mass in young and middle aged females and males A meta-analysis of the effect of calcium intake on bone mass in young and middle aged females and males A meta-analysis of the effect of calcium intake on bone mass in young and middle aged females and males Welten D C, Kemper H C, Post G B, van Staveren W A Authors' objectives To evaluate the effect of calcium intake on bone mass in adults between the ages of 18 and 50 years. Searching (...) MEDLINE was searched from 1966 to 1994 for articles published in English, French, German or Dutch using the keywords 'calcium' and 'bone mass'. A private database was also searched for references in relevant publications. Study selection Study designs of evaluations included in the review Cross-sectional, longitudinal and intervention studies were included. Specific interventions included in the review Calcium intake ranging from 436 to 1,500 mg/day. Participants included in the review Pre-menopausal

DARE.1995

319. Cost-effectiveness of preventing hip fractures in the elderly population using vitamin D and calcium

Cost-effectiveness of preventing hip fractures in the elderly population using vitamin D and calcium Cost-effectiveness of preventing hip fractures in the elderly population using vitamin D and calcium Cost-effectiveness of preventing hip fractures in the elderly population using vitamin D and calcium Torgerson D J, Kanis J A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) , the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Ergocalciferol and calciferol (Vitamins D) and calcium supplementation. Type of intervention Secondary prevention. Economic study type Cost-effectiveness analysis. Study population Elderly women with and without a low body mass index (BMI) (high risk group). Setting Community and nursing homes. Dates to which data relate The effectiveness data relate

NHS Economic Evaluation Database.1995

320. The costs and effects of switching calcium channel blockers: evidence from Medicaid claims data

The costs and effects of switching calcium channel blockers: evidence from Medicaid claims data The costs and effects of switching calcium channel blockers: evidence from Medicaid claims data The costs and effects of switching calcium channel blockers: evidence from Medicaid claims data Simon W B, Rizzo J A, Stoddard M, Smith M E Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Calcium channel blocker therapies for hypertension: specifically Procardia XL and Adalat CC. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population Hypertensive patients without angina who were already receiving Procardia XL. Setting Hospital. The economic study was carried out in Pennsylvania, USA. Dates

NHS Economic Evaluation Database.1995